Suxamethonium was administered to 225 children agedfram one to sixteen years, in doses varyingfram 0.1 to 0.5 mg/kg. Dose responses were determined. ED95 was 445 pg/kg in one to four year olds, 454 pg/kg in the five to ten years group and 270 pg/kg in eleven to fifteen year olds (P < 0.05). There is a wider variability in patient responses to 0.1 and 0.2 mg /kg than to the higher doses.
Suxamethonium was introduced in 1952 and has maintained an important role in anaesthetic practice because of its rapid onset of action, a property of particular importance in emergency anaesthesia. The commonly used dose of 1.0 mg/kg, or sometimes more, was established early as one which regularly paralysed patients for long enough to intubate them without undue haste. Few studies have been undertaken to determine whether this dose is appropriate. I ,2 This study was initiated in 1980 to establish control values for the small doses of suxamethonium used in later studies on patients with abnormal responses to suxamethonium. 3 Subsequently, the study was extended so that agerelated dose-response curves could be developed. The results form the first section of the paper. The second section is a study on the degree of paralysis, rate of onset and recovery to 50% activity in various age groups of children who were given suxamethonium 1.0 mg/kg.
METHODS
A total of 287 children aged from one to sixteen years was studied, using the integrated electromyograph (IEMG) following intravenous induction of anaesthesia.
Group A. In the first group of 225 patients, stimulating electrodes were placed over the median nerve at the wrist, with the recording electrodes over opponens pollicis and the dorsal aspect of the thumb and a neutral on the forearm.4 Having set the gain so that the IEMG twitch height was 100%, single supramaximal stimuli were given every ten seconds. The patients were then given a dose of suxamethonium, either 0.1,0.2,0.3, or 0.5 mg/kg. The level of maximum twitch depression was then recorded.
The results were treated in two ways: (a) To determine dose-response curves for children in age groups one to four, five to ten and eleven to fifteen years, the levels of neuromuscular block were transformed to probit values and the doses were converted to logarithmic values. Linear regression analysis was used to derive the mean logprobit dose-response curves with 95% confidence limits for different age groups. The statistical difference was analysed by the method described by Litchfield and Wilcoxon. 5 (b) Bar graphs were used to illustrate the range of responses at each dose leveL Graup B. A study in 62 children given suxamethonium 1.0 mg/kg determined the maximum neuromuscular block, time from injection to maximum neuromuscular block (onset time) and time from injection to 50% recovery (recovery time), in children in age groups one to four, five to ten and eleven to fifteen years. This was conducted using the Datex Relaxograph with single supramaximal ulnar nerve stimulation at 0.1 Hz. The recording electrodes were placed over the adductor pollicis muscle and the base of the middle finger. Analysis of variance was used to compare different age groups. A Pvalue < 0.05 was regarded as significant. Values are expressed as means (SEM).
RESULTS
Group A. Table 1 shows the neuromuscular block produced by small doses of suxamethonium in different age groups of patients. In general, the neuromuscular block produced by a constant dose/kg of suxamethonium was greatest among patients of eleven to fifteen years. Figure 1 shows the distribution graph of responses following each suxamethonium dose. In general, there is a wider range of responses for smaller doses of suxamethonium. Figure 2 shows the dose-response curves of suxamethonium for different age groups of patients and Table 2 the ED50 and ED95 doses of suxamethonium for the same age groups of patients. The dose-response curves are parallel and the dose-response of patients eleven to fifteen years old is significantly less than the dose-responses of younger patients (P< 0.05).
Group B. Table 3 shows the EMG responses of patients to suxamethonium 1.0 mg/kg. The maximal neuromuscular block and the onset times are comparable between the patient groups but the recovery time is longest in patients eleven to fifteen years old (P < 0.05).
DISCUSSION
A. Recently Meakin et at. 1 have measured doseresponses in a small series of neonates, infants and children. They showed that the ED95 for suxamethonium in neonates was 620 ~g/kg. In infants from one to twelve months of age it was 729 ~g/kg and in young children (one to five years) it decreased to 423 ~g/kg. The dose-response curves were drawn as parallel lines but the neonatal points suggested that a line tilted to the right (i.e. lower slope value) may have been more accurate, resulting in a higher ED95 in neonates (about 900 Our study complements that of Meakin's group. Our results agree with their findings in the one to four year age group (ED95 445 jlg/kg) and adds two older age groups five to ten years (ED95 454 Ilg/kg) and eleven to fifteen years, who had a lower ED95 of 270 Ilg/kg. There is a distinct trend for more profound paralysis to be produced by small doses of suxamethonium as children become older than ten or eleven years and approach puberty. The children in our oldest age group had ED95 fairly similar to that reported from Montreal in adults (ED95 310 llg/kg). 7 These doses are lower than the dose of 51 0 Ilg/kg reported by Chestnut et at. 8 Our results showed a wide range of response to the lower doses (Figure 1) , varying from 27 to 100% at 0.3 mg/kg. This range is comparable to that seen in adults. Many factors may account for this variation, including changes which occur with age. Among these are the amount of body fat, the proportion of muscle mass to body weight, the relative dimensions of body fluid compartments, muscle blood flow and cholinesterase activity.
For example, in obese patients the volume of distribution of suxamethonium is decreased and consequently they have a lower ED 95 . Doseresponse studies of muscle relaxants could be used to estimate the proportion of excess fat in patients. In infants, muscle mass is relatively less than in older children, which might decrease dose requirements. However, they have a large extracellular fluid volume (40-45% at birth) which increases the volume in which an ionised drug such as suxamethonium is distributed and may explain the observed increase in requirements. At puberty, changes in muscle mass and fat distribution may also influence dose requirements.
Cholinesterase activity is low both with certain genetic variants and with conditions such as liver disease and pregnancy.9 It is also low in newborns up to six months of age, 10-12 is 30% higher between five and six years and then declines towards adult levels. 13 Thus, breakdown may be more rapid in the five years age group and lead to a greater dose requirement. This may contribute to the higher ED95 in children. However, the cholinesterase level declines at an earlier age than that at which the ED95 decreases (around eleven years of age).
B. The second section of this paper demonstrates that suxamethonium 1.0 mglkg paralyses all children over one year of age. The rate of onset (time from injection to maximum depression) was similar in all age groups. The duration of action (measured here as time from injection to 50% recovery) became longer as age increased, but again the relatively greater dosage compared to ED95 in adolescents (four times compared to twice in children) would prolong their recovery more than the younger group. (11) 8.2 ± I (7)t* Shorter onset times have been noted in younger patients for vecuronium,14 atracurium,15 pancuronium,16 alcuronium and d-tubocurarine. 17 This is probably related to cardiac output which is higher when related to body weight in infants, as well as the shorter distance the blood has to travel and the shorter circulation time.
In conclusion, we have tried to fill some of the gaps in the information about suxamethonium in children. We have shown that I mg/kg is a more than adequate dose in patients over one year and that the doses commonly used are several times greater than those needed, especially in adults. Perhaps some of the complications of the use of suxamethonium, such as chest pains, bradycardia and the dangerous rises in serum potassium in bums, might be minimised ifthe dose was reduced sufficiently.
